BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7911394)

  • 1. Reversal of multidrug resistance by RU 486.
    Gruol DJ; Zee MC; Trotter J; Bourgeois S
    Cancer Res; 1994 Jun; 54(12):3088-91. PubMed ID: 7911394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
    Yang JM; Goldenberg S; Gottesman MM; Hait WN
    Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of reversal of daunorubicin resistance in HL60/AR cells by cyclosporin A.
    Gollapudi S; Gupta S
    Anticancer Res; 1992; 12(6B):2127-32. PubMed ID: 1363515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis.
    Bourgeois S; Gruol DJ; Newby RF; Rajah FM
    Mol Endocrinol; 1993 Jul; 7(7):840-51. PubMed ID: 8105374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance mediated by P-glycoproteins.
    Schinkel AH; Borst P
    Semin Cancer Biol; 1991 Aug; 2(4):213-26. PubMed ID: 1680493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of multidrug-resistant pituitary tumor cells.
    Nelson EJ; Hinkle PM
    Endocrinology; 1992 Jun; 130(6):3246-56. PubMed ID: 1350759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescent verapamil derivative for monitoring activity of the multidrug transporter.
    Lelong IH; Guzikowski AP; Haugland RP; Pastan I; Gottesman MM; Willingham MC
    Mol Pharmacol; 1991 Oct; 40(4):490-4. PubMed ID: 1681415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates.
    Stein WD; Cardarelli C; Pastan I; Gottesman MM
    Mol Pharmacol; 1994 Apr; 45(4):763-72. PubMed ID: 7910372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance. Clinical opportunities in diagnosis and circumvention.
    Chan HS; DeBoer G; Thorner PS; Haddad G; Gallie BL; Ling V
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):383-410. PubMed ID: 7913705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788.
    Efferth T; Dunn TA; Berlion M; Langenbahn H; Pommerenke EW; Volm M
    Anticancer Res; 1993; 13(4):905-8. PubMed ID: 8102519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of rhodamine 123 binding to P-glycoprotein in human multidrug-resistant cells.
    Nare B; Prichard RK; Georges E
    Mol Pharmacol; 1994 Jun; 45(6):1145-52. PubMed ID: 7912815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells.
    Molnár J; Hevér A; Fakla I; Fischer J; Ocsovski I; Aszalós A
    Anticancer Res; 1997; 17(1A):481-6. PubMed ID: 9066699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype.
    Mi Q; Cui B; Silva GL; Lantvit D; Lim E; Chai H; You M; Hollingshead MG; Mayo JG; Kinghorn AD; Pezzuto JM
    Cancer Res; 2001 May; 61(10):4030-7. PubMed ID: 11358822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.
    Piwnica-Worms D; Chiu ML; Budding M; Kronauge JF; Kramer RA; Croop JM
    Cancer Res; 1993 Mar; 53(5):977-84. PubMed ID: 8094997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance.
    Smith CD; Carmeli S; Moore RE; Patterson GM
    Cancer Res; 1993 Mar; 53(6):1343-7. PubMed ID: 8095179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells.
    Kavallaris M; Madafiglio J; Norris MD; Haber M
    Biochem Biophys Res Commun; 1993 Jan; 190(1):79-85. PubMed ID: 8093660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs transported by P-glycoprotein inhibit a 40 pS outwardly rectifying chloride channel.
    Bear CE
    Biochem Biophys Res Commun; 1994 Apr; 200(1):513-21. PubMed ID: 7909435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
    Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistant transgenic mice as a novel pharmacologic tool.
    Mickisch GH; Pastan I; Gottesman MM
    Bioessays; 1991 Aug; 13(8):381-7. PubMed ID: 1683231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.